{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:56:56Z","timestamp":1769518616490,"version":"3.49.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11926-022-01065-7","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T10:05:39Z","timestamp":1651226739000},"page":"119-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cannabis for Rheumatic Disease Pain: a Review of Current Literature"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-6476","authenticated-orcid":false,"given":"William Benjamin","family":"Nowell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-4940","authenticated-orcid":false,"given":"Kelly","family":"Gavigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"L. Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"7","key":"1065_CR1","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s11606-020-05800-7","volume":"35","author":"P Azcarate","year":"2020","unstructured":"Azcarate P, Zhang A, Keyhani S, Steigerwald S, Ishida J, Cohen B. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. J Gen Intern Med. 2020;35(7):1979\u201386.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"1065_CR2","doi-asserted-by":"publisher","first-page":"e1911936","DOI":"10.1001\/jamanetworkopen.2019.11936","volume":"2","author":"H Dai","year":"2019","unstructured":"Dai H, Richter KP. A national survey of marijuana use among US adults with medical conditions, 2016\u20132017. JAMA Netw Open. 2019;2(9):e1911936.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/acr2.11138","volume":"2","author":"M-A Fitzcharles","year":"2020","unstructured":"Fitzcharles M-A, Rampakakis E, Sampalis J, Shir Y, Cohen M, Starr M, et al. Medical Cannabis use by rheumatology patients following recreational legalization: a prospective observational Study of 1000 patients in Canada. ACR Open Rheumatol. 2020;2(5):286\u201393.","journal-title":"ACR Open Rheumatol"},{"key":"1065_CR4","doi-asserted-by":"crossref","unstructured":"Fitzcharles M-A, Rampakakis E, Shir Y, Sampalis J, Cohen M, Starr M, et al. Use of medical cannabis by patients with fibromyalgia\u00a0in Canada after cannabis legalisation: a prospective cross-sectional study.\u00a0Clin Exp Rheumatol.\u00a0\u00a02021;39 Suppl 130(3):115\u20139.","DOI":"10.55563\/clinexprheumatol\/qcyet7"},{"key":"1065_CR5","unstructured":"Gavigan K, Venkatachalam S, Curtis J, Wiedmeyer C, Sydnor-Campbell T, Stake C, et al. Legal matters: attitudes regarding marijuana for medical use among patients with rheumatic and musculoskeletal disease [abstract]. Arthritis Rheumatol. 2019;71(10). https:\/\/acrabstracts.org\/abstract\/legal-matters attitudes-regarding-marijuana-for-medical-use-among-patients-with-rheumatic-and musculoskeletal-disease\/. Accessed 29 March  2022.\u00a0"},{"key":"1065_CR6","unstructured":"Rampakakis E, Shir Y, Sampalis J, Cohen M, Starr M, H\u00e4user W, Fitzcharles M. Medical cannabis in ankylosing spondylitis following recreational legalization: a prospective cross-sectional study [abstract]. Arthritis Rheumatol. 2020;72(10). https:\/\/acrabstracts.org\/abstract\/medical-cannabis-in-ankylosing spondylitis-following-recreational-legalization-a-prospective-cross-sectional-study\/. Accessed 29 March 2022.\u00a0"},{"issue":"12","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11926-016-0625-5","volume":"18","author":"M-A Fitzcharles","year":"2016","unstructured":"Fitzcharles M-A, H\u00e4user W. Cannabinoids in the management of musculoskeletal or rheumatic diseases. Curr Rheumatol Rep. 2016;18(12):76.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/acr.22727","volume":"68","author":"MA Fitzcharles","year":"2016","unstructured":"Fitzcharles MA, Ste-Marie PA, H\u00e4user W, Clauw DJ, Jamal S, Karsh J, et al. Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. Arthritis Care Res (Hoboken). 2016;68(5):681\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"1065_CR9","doi-asserted-by":"publisher","first-page":"102409","DOI":"10.1016\/j.autrev.2019.102409","volume":"18","author":"P Sarzi-Puttini","year":"2019","unstructured":"Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles MA, Marotto D, H\u00e4user W. Cannabinoids in the treatment of rheumatic diseases: pros and cons. Autoimmun Rev. 2019;18(12):102409.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"1065_CR10","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cbdv.200790144","volume":"4","author":"EB Russo","year":"2007","unstructured":"Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614\u201348.","journal-title":"Chem Biodivers"},{"key":"1065_CR11","unstructured":"DEA announces actions related to marijuana and industrial hemp [press release]. U. S. Drug Enforcement Agency. 2016."},{"key":"1065_CR12","unstructured":"FDA and cannabis: research and drug approval process. US Food and Drug Administration. Updated October 1, 2020. https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-and-cannabis-research-and-drug-approval-process#:~:text=The%20agency%20has%2C%20however%2C%20approved,from%20a%20licensed%20healthcare%20provider. Accessed 29 March\u00a02022."},{"key":"1065_CR13","unstructured":"Solutions DG. Map of Marijuana Legality by State. Disa.com. 2021.\u00a0 https:\/\/disa.com\/map-of-marijuana-legality-by-state.\u00a0Accessed 29\u00a0March 2022."},{"key":"1065_CR14","unstructured":"Americans for Safe Access. Federal Marijuana Law 2018.\u00a0https:\/\/www.safeaccessnow.org\/federal_marijuana_law. Accessed 29\u00a0March 2022."},{"key":"1065_CR15","unstructured":"Lampe JR. State marijuana \u201clegalization\u201d and federal drug law: a brief overview for congress.\u00a02020. https:\/\/sgp.fas.org\/crs\/misc\/LSB10482.pdf.\u00a0Accessed 29\u00a0March 2022."},{"key":"1065_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.drugalcdep.2018.01.022","volume":"186","author":"B Han","year":"2018","unstructured":"Han B, Compton WM, Blanco C, Jones CM. Trends in and correlates of medical marijuana use among adults in the United States. Drug Alcohol Depend. 2018;186:120\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"1065_CR17","unstructured":"Wipfler K, Shaw Y, Simon T, Cornish A, England B, Ogdie A, et al. Experiences of patients with rheumatic diseases in the US during the early months of the COVID-19 pandemic [abstract]. Arthritis Rheumatol. 2020;72(10). https:\/\/acrabstracts.org\/abstract\/experiences-of-patients-with-rheumatic-diseases-in the-us-during-the-early-months-of-the-covid-19-pandemic\/. Accessed 29\u00a0March 2022.\u00a0"},{"key":"1065_CR18","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); January 12, 2017."},{"key":"1065_CR19","unstructured":"Wipfler K, Simon T, Katz P, Wolfe F, Michaud K. Cannabis use among patients in a large US rheumatic disease registry [abstract]. Arthritis Rheumatol. 2019;71(10). Accessed 29 March  2022. https:\/\/acrabstracts.org\/abstract\/cannabis-use-among-patients-in-a-large-us-rheumatic-disease-registry\/."},{"key":"1065_CR20","unstructured":"U.S. voter support for marijuana hits new high; Quinnipiac University National poll finds; 76 percent say their finances are excellent or good [press release]. Quinnipiac University-Poll. 2017.\u00a0\u00a0Accessed 29 March 2022. https:\/\/poll.qu.edu\/Poll-Release-Legacy?releaseid=2453"},{"key":"1065_CR21","unstructured":"Swift A. Support for legal marijuana use up to 60% in U.S. Gallup. Gallup. 2016.\u00a0Accessed March 29, 2022.\u00a0\u00a0https:\/\/news.gallup.com\/poll\/196550\/support-legal-marijuana.aspx."},{"key":"1065_CR22","doi-asserted-by":"publisher","unstructured":"Wipfler K, Simon TA, Katz P, Wolfe F, Michaud K. Increase in cannabis use among adults with rheumatic diseases: results from a 2014-2019 US observational study [published online ahead of print, 2021 Jul 15]. Arthritis Care Res (Hoboken). 2021;\u00a0https:\/\/doi.org\/10.1002\/acr.24752","DOI":"10.1002\/acr.24752"},{"key":"1065_CR23","volume-title":"Legal matters: attitudes regarding marijuana for medical use among patients with rheumatic and musculoskeletal disease","year":"2019","unstructured":"Gavigan K, Venkatachalam S, Curtis J, Wiedmeyer C, Sydnor-Campbell T, Stake C, et al editors. Legal matters: attitudes regarding marijuana for medical use among patients with rheumatic and musculoskeletal disease. Atlanta: American College of Rheumatology; 2019."},{"key":"1065_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2017.08.010","volume":"180","author":"AB Evanoff","year":"2017","unstructured":"Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ. Physicians-in-training are not prepared to prescribe medical marijuana. Drug Alcohol Depend. 2017;180:151\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1065_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.22267","volume":"66","author":"M-A Fitzcharles","year":"2014","unstructured":"Fitzcharles M-A, Clauw DJ, Ste-Marie PA, Shir Y. The dilemma of medical marijuana use by rheumatology patients. Arthritis Care Res. 2014;66(6):797\u2013801.","journal-title":"Arthritis Care Res"},{"issue":"15","key":"1065_CR26","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2013United States, 2016. JAMA. 2016;315(15):1624\u201345.","journal-title":"JAMA"},{"issue":"2","key":"1065_CR27","first-page":"e6963","volume":"12","author":"A Genova","year":"2020","unstructured":"Genova A, Dix O, Thakur M, Sangha PS. Chronic non-cancer pain management and addiction: a review. Cureus. 2020;12(2):e6963.","journal-title":"Cureus"},{"issue":"4","key":"1065_CR28","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/j.pain.0000000000002113","volume":"162","author":"MA Shraim","year":"2021","unstructured":"Shraim MA, Mass\u00e9-Alarie H, Hodges PW. Methods to discriminate between mechanism-based categories of pain experienced in the musculoskeletal system: a systematic review. Pain. 2021;162(4):1007\u201337.","journal-title":"Pain"},{"key":"1065_CR29","doi-asserted-by":"publisher","unstructured":"M\u00fccke M, Phillips T, Radbruch L, Petzke F, H\u00e4user W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182. https:\/\/doi.org\/10.1002\/14651858.CD012182.pub2","DOI":"10.1002\/14651858.CD012182.pub2"},{"issue":"11","key":"1065_CR30","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1136\/annrheumdis-2011-201201","volume":"71","author":"SJ Bartlett","year":"2012","unstructured":"Bartlett SJ, Hewlett S, Bingham CO, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis. 2012;71(11):1855.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1065_CR31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/pm\/pnz255","volume":"22","author":"E Bucourt","year":"2021","unstructured":"Bucourt E, Martaill\u00e9 V, Goupille P, Joncker-Vannier I, Huttenberger B, R\u00e9veill\u00e8re C, et al. A comparative study of fibromyalgia, rheumatoid arthritis, spondyloarthritis, and Sj\u00f6gren\u2019s syndrome; impact of the disease on quality of life, psychological adjustment, and use of coping strategies. Pain Med. 2021;22(2):372\u201381.","journal-title":"Pain Med"},{"issue":"7","key":"1065_CR32","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s11136-020-02457-x","volume":"29","author":"CM Galvez-S\u00e1nchez","year":"2020","unstructured":"Galvez-S\u00e1nchez CM, Montoro CI, Duschek S, Del Paso GAR. Pain catastrophizing mediates the negative influence of pain and trait-anxiety on health-related quality of life in fibromyalgia. Qual Life Res. 2020;29(7):1871\u201381.","journal-title":"Qual Life Res"},{"issue":"1","key":"1065_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-021-02430-0","volume":"23","author":"WB Nowell","year":"2021","unstructured":"Nowell WB, Gavigan K, Kannowski CL, Cai Z, Hunter T, Venkatachalam S, et al. Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. Arthritis Res Ther. 2021;23(1):53.","journal-title":"Arthritis Res Ther"},{"key":"1065_CR34","unstructured":"Walker HK, Hall WD, Hurst JW eds. Clinical methods: the history, physical, and laboratory examinations, 3rd ed. Boston: Butterworths. 1990."},{"issue":"6","key":"1065_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s11926-012-0285-z","volume":"14","author":"SL Murphy","year":"2012","unstructured":"Murphy SL, Phillips K, Williams DA, Clauw DJ. The role of the central nervous system in osteoarthritis pain and implications for rehabilitation. Curr Rheumatol Rep. 2012;14(6):576\u201382.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"1065_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1021\/acs.chemrev.5b00411","volume":"116","author":"M Aghazadeh Tabrizi","year":"2016","unstructured":"Aghazadeh Tabrizi M, Baraldi PG, Borea PA, Varani K. Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB2 receptor agonists. Chem Rev. 2016;116(2):519\u201360.","journal-title":"Chem Rev"},{"issue":"3","key":"1065_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5152\/eurjrheum.2017.17025","volume":"4","author":"N Barrie","year":"2017","unstructured":"Barrie N, Manolios N. The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol. 2017;4(3):210\u20138.","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"1065_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2013.12.042","volume":"233","author":"V Chiurchi\u00f9","year":"2014","unstructured":"Chiurchi\u00f9 V, Lanuti M, Catanzaro G, Fezza F, Rapino C, Maccarrone M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis. 2014;233(1):55\u201363.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1065_CR39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.intimp.2015.03.006","volume":"26","author":"H Gui","year":"2015","unstructured":"Gui H, Tong Q, Qu W, Mao CM, Dai SM. The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. Int Immunopharmacol. 2015;26(1):86\u201391.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1065_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.dld.2010.08.010","volume":"43","author":"L Huang","year":"2011","unstructured":"Huang L, Quinn MA, Frampton GA, Golden LE, DeMorrow S. Recent advances in the understanding of the role of the endocannabinoid system in liver diseases. Dig Liver Dis. 2011;43(3):188\u201393.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"1065_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","volume":"17","author":"C Silvestri","year":"2013","unstructured":"Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013;17(4):475\u201390.","journal-title":"Cell Metab"},{"key":"1065_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/1476-511X-10-194","volume":"10","author":"T You","year":"2011","unstructured":"You T, Disanzo BL, Wang X, Yang R, Gong D. Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids Health Dis. 2011;10:194.","journal-title":"Lipids Health Dis"},{"issue":"7","key":"1065_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/1756-185X.13146","volume":"20","author":"N Barrie","year":"2017","unstructured":"Barrie N, Kuruppu V, Manolios E, Ali M, Moghaddam M, Manolios N. Endocannabinoids in arthritis: current views and perspective. Int J Rheum Dis. 2017;20(7):789\u201397.","journal-title":"Int J Rheum Dis"},{"key":"1065_CR44","doi-asserted-by":"publisher","first-page":"107495","DOI":"10.1016\/j.pharmthera.2020.107495","volume":"209","author":"CA Bouchet","year":"2020","unstructured":"Bouchet CA, Ingram SL. Cannabinoids in the descending pain modulatory circuit: role in inflammation. Pharmacol Ther. 2020;209:107495.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1065_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/neu.20080","volume":"61","author":"BF Cravatt","year":"2004","unstructured":"Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004;61(1):149\u201360.","journal-title":"J Neurobiol"},{"key":"1065_CR46","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/1471-2474-15-275","volume":"15","author":"S Fukuda","year":"2014","unstructured":"Fukuda S, Kohsaka H, Takayasu A, Yokoyama W, Miyabe C, Miyabe Y, et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet Disord. 2014;15:275.","journal-title":"BMC Musculoskelet Disord"},{"issue":"23\u201324","key":"1065_CR47","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/0024-3205(95)00195-C","volume":"56","author":"WJ Martin","year":"1995","unstructured":"Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 1995;56(23\u201324):2103\u20139.","journal-title":"Life Sci"},{"issue":"1","key":"1065_CR48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/npp.2015.166","volume":"41","author":"M Morena","year":"2016","unstructured":"Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41(1):80\u2013102.","journal-title":"Neuropsychopharmacology"},{"issue":"18","key":"1065_CR49","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1073\/pnas.1834309100","volume":"100","author":"MM Ibrahim","year":"2003","unstructured":"Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003;100(18):10529\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1607","key":"1065_CR50","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1098\/rstb.2011.0382","volume":"367","author":"V Di Marzo","year":"2012","unstructured":"Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc B Biol Sci. 2012;367(1607):3216\u201328.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"1065_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1749-6632.2009.05301.x","volume":"1193","author":"HG Schaible","year":"2010","unstructured":"Schaible HG, von Banchet GS, Boettger MK, Br\u00e4uer R, Gajda M, Richter F, et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci. 2010;1193:60\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"1065_CR52","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","volume":"96","author":"A Ligresti","year":"2016","unstructured":"Ligresti A, De Petrocellis L, Di Marzo V. From Phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016;96(4):1593\u2013659.","journal-title":"Physiol Rev"},{"issue":"2","key":"1065_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1570159X17666190903103923","volume":"18","author":"SG Ferber","year":"2020","unstructured":"Ferber SG, Namdar D, Hen-Shoval D, Eger G, Koltai H, Shoval G, et al. The \u201centourage effect\u201d: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol. 2020;18(2):87\u201396.","journal-title":"Curr Neuropharmacol"},{"key":"1065_CR54","doi-asserted-by":"publisher","unstructured":"Katz-Talmor D, Katz I, Porat-Katz B-S, Shoenfeld Y. Cannabinoids for the treatment of rheumatic diseases \u2014 where do we stand? Nat Rev Rheumatol. 2018;14(8):488\u201398. https:\/\/doi.org\/10.1038\/s41584-018-0025-5.","DOI":"10.1038\/s41584-018-0025-5"},{"key":"1065_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fphar.2020.00359","volume":"11","author":"DB Finlay","year":"2020","unstructured":"Finlay DB, Sircombe KJ, Nimick M, Jones C, Glass M. Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Front Pharmacol. 2020;11:359.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1065_CR56","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","volume":"163","author":"EB Russo","year":"2011","unstructured":"Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344\u201364.","journal-title":"Br J Pharmacol"},{"key":"1065_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.apha.2017.03.004","volume":"80","author":"EB Russo","year":"2017","unstructured":"Russo EB, Marcu J. Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol. 2017;80:67\u2013134.","journal-title":"Adv Pharmacol"},{"issue":"6","key":"1065_CR58","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.phymed.2014.01.009","volume":"21","author":"CP Jiang","year":"2014","unstructured":"Jiang CP, He X, Yang XL, Zhang SL, Li H, Song ZJ, et al. Anti-rheumatoid arthritic activity of flavonoids from Daphne genkwa. Phytomedicine. 2014;21(6):830\u20137.","journal-title":"Phytomedicine"},{"issue":"6","key":"1065_CR59","doi-asserted-by":"publisher","first-page":"E755","DOI":"10.36076\/ppj.20.5.E755","volume":"20","author":"J Aviram","year":"2017","unstructured":"Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755\u201396.","journal-title":"Pain Physician"},{"issue":"6","key":"1065_CR60","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/epi.16542","volume":"61","author":"M Bialer","year":"2020","unstructured":"Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020;61(6):1082\u20139.","journal-title":"Epilepsia"},{"issue":"5","key":"1065_CR61","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00520-019-05280-4","volume":"28","author":"R Chow","year":"2020","unstructured":"Chow R, Valdez C, Chow N, Zhang D, Im J, Sodhi E, et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. Support Care Cancer. 2020;28(5):2095\u2013103.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1065_CR62","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/pm\/pnab050","volume":"22","author":"I Dykukha","year":"2021","unstructured":"Dykukha I, Malessa R, Essner U, \u00dcberall MA. Nabiximols in chronic neuropathic pain: a meta-analysis of randomized placebo-controlled trials. Pain Med. 2021;22(4):861\u201374.","journal-title":"Pain Med"},{"issue":"1","key":"1065_CR63","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13643-019-1243-x","volume":"8","author":"M Pratt","year":"2019","unstructured":"Pratt M, Stevens A, Thuku M, Butler C, Skidmore B, Wieland LS, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev. 2019;8(1):320.","journal-title":"Syst Rev"},{"issue":"4","key":"1065_CR64","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.bbrc.2007.05.178","volume":"359","author":"A Engler","year":"2007","unstructured":"Engler A, Aeschlimann A, Simmen BR, Michel BA, Gay RE, Gay S, et al. Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem Biophys Res Commun. 2007;359(4):884\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1065_CR65","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/rheumatology\/ket447","volume":"53","author":"H Gui","year":"2014","unstructured":"Gui H, Liu X, Wang ZW, He DY, Su DF, Dai SM. Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. Rheumatology (Oxford). 2014;53(5):802\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1065_CR66","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41419-020-02892-1","volume":"11","author":"T Lowin","year":"2020","unstructured":"Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020;11(8):714.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1065_CR67","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1186\/ar2401","volume":"10","author":"D Richardson","year":"2008","unstructured":"Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R43.","journal-title":"Arthritis Res Ther"},{"key":"1065_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12950-016-0114-7","volume":"13","author":"T Lowin","year":"2016","unstructured":"Lowin T, Pongratz G, Straub RH. The synthetic cannabinoid WIN55,212\u20132 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets. J Inflamm (Lond). 2016;13:15.","journal-title":"J Inflamm (Lond)"},{"issue":"4","key":"1065_CR69","first-page":"574","volume":"26","author":"E Selvi","year":"2008","unstructured":"Selvi E, Lorenzini S, Garcia-Gonzalez E, Maggio R, Lazzerini PE, Capecchi PL, et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol. 2008;26(4):574\u201381.","journal-title":"Clin Exp Rheumatol"},{"key":"1065_CR70","unstructured":"Lowin T, Schneider M, Pongratz G. The non-psychotropic phytocannabinoids cannabigerol and tetrahydrocannabinolic acid inhibit rheumatoid arthritis synovial ribroblast function by targeting the wasabi receptor TRPA1 [abstract]. Arthritis Rheumatol. 2020;72(10). https:\/\/acrabstracts.org\/abstract\/the-non-psychotropic-phytocannabinoids cannabigerol-and-tetrahydrocannabinolic-acid-inhibit-rheumatoid-arthritis-synovial fibroblast-function-by-targeting-the-wasabi-receptor-trpa1\/. Accessed 29\u00a0March 2022.\u00a0"},{"issue":"6","key":"1065_CR71","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.imbio.2014.12.012","volume":"220","author":"H Gui","year":"2015","unstructured":"Gui H, Liu X, Liu LR, Su DF, Dai SM. Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis. Immunobiology. 2015;220(6):817\u201322.","journal-title":"Immunobiology"},{"issue":"6","key":"1065_CR72","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.autrev.2016.02.008","volume":"15","author":"V Katchan","year":"2016","unstructured":"Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun Rev. 2016;15(6):513\u201328.","journal-title":"Autoimmun Rev"},{"issue":"17","key":"1065_CR73","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","volume":"97","author":"AM Malfait","year":"2000","unstructured":"Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1065_CR74","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/art.20050","volume":"50","author":"PF Sumariwalla","year":"2004","unstructured":"Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 2004;50(3):985\u201398.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1065_CR75","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/jpet.109.164806","volume":"334","author":"PS Naidu","year":"2010","unstructured":"Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther. 2010;334(1):182\u201390.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1065_CR76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","volume":"45","author":"DR Blake","year":"2006","unstructured":"Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50\u20132.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1065_CR77","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/acm.2017.0184","volume":"24","author":"D Bruce","year":"2018","unstructured":"Bruce D, Brady JP, Foster E, Shattell M. Preferences for medical marijuana over prescription medications among persons living with chronic conditions: alternative, complementary, and tapering uses. J Altern Complement Med. 2018;24(2):146\u201353.","journal-title":"J Altern Complement Med"},{"key":"1065_CR78","doi-asserted-by":"publisher","unstructured":"Gavigan K, Stradford L, Booth K, Wang K, Fields M, Curtis J, et al. Understanding the patient perspective: benefits and risks of pain treatment for osteoarthritis and chronic lower back pain. 2019.\u00a0\u00a0PAINWeek Abstract Book 2019, Postgraduate Medicine. 131(1):1\u2013130. https:\/\/doi.org\/10.1080\/00325481.2019.1655695","DOI":"10.1080\/00325481.2019.1655695"},{"key":"1065_CR79","unstructured":"Goodwin H, Porter A, Edwards M, Libman B. Evaluation of marijuana and cannabidiol use in the rheumatologic population from a patient and clinician perspective: a survey-based study.\u00a0[abstract]\u00a0Arthritis Rheumatol. 2019;71(10). https:\/\/acrabstracts.org\/abstract\/evaluation-of-marijuana-and-cannabidiol-use-in-the-rheumatologic-population-from-a-patient-and-clinician-perspective-a-survey-based-study\/. Accessed 29\u00a0March 2022.\u00a0"},{"key":"1065_CR80","unstructured":"Guillouard M, Authier N, Pereira B, Soubrier M, Mathieu S. Cannabis use assessment and its impact on pain in rheumatic diseases: a systematic review and meta-analysis.\u00a0\u00a0[abstract]. Arthritis Rheumatol. 2020;72(10). https:\/\/acrabstracts.org\/abstract\/cannabis-use-assessment-and-its-impact-on-pain-in-rheumatic-diseases-a-systematic-review-and-meta-analysis\/. Accessed 29\u00a0March\u00a02022."},{"issue":"6","key":"1065_CR81","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.3892\/mmr.2016.5137","volume":"13","author":"Y Kong","year":"2016","unstructured":"Kong Y, Wang W, Zhang C, Wu Y, Liu Y, Zhou X. Cannabinoid WIN-55,212\u20132 mesylate inhibits ADAMTS-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1. Mol Med Rep. 2016;13(6):4569\u201376.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1065_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/can.2015.0001","volume":"1","author":"SL Dunn","year":"2016","unstructured":"Dunn SL, Wilkinson JM, Crawford A, Bunning RAD, Le Maitre CL. Expression of cannabinoid receptors in human osteoarthritic cartilage: implications for future therapies. Cannabis Cannabinoid Res. 2016;1(1):3\u201315.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1065_CR83","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.coph.2018.03.012","volume":"40","author":"M O\u2019Brien","year":"2018","unstructured":"O\u2019Brien M, McDougall JJ. Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids. Curr Opin Pharmacol. 2018;40:104\u20139.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"1065_CR84","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejp.818","volume":"20","author":"DC Hammell","year":"2016","unstructured":"Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936\u201348.","journal-title":"Eur J Pain"},{"issue":"10","key":"1065_CR85","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1097\/j.pain.0000000000000260","volume":"156","author":"C La Porta","year":"2015","unstructured":"La Porta C, Bura SA, Llorente-Onaindia J, Pastor A, Navarrete F, Garc\u00eda-Guti\u00e9rrez MS, et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain. 2015;156(10):2001\u201312.","journal-title":"Pain"},{"issue":"12","key":"1065_CR86","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1097\/j.pain.0000000000001052","volume":"158","author":"HT Philpott","year":"2017","unstructured":"Philpott HT, O\u2019Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442\u201351.","journal-title":"Pain"},{"issue":"3","key":"1065_CR87","first-page":"e7375","volume":"12","author":"CA Gusho","year":"2020","unstructured":"Gusho CA, Court T. Cannabidiol: a brief review of its therapeutic and pharmacologic efficacy in the management of joint disease. Cureus. 2020;12(3):e7375.","journal-title":"Cureus"},{"key":"1065_CR88","doi-asserted-by":"crossref","unstructured":"Johal H, Vannabouathong C, Chang Y, Zhu M, Bhandari M. Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? Ther Adv Musculoskelet Dis. 2020;12:1759720X20937968.","DOI":"10.1177\/1759720X20937968"},{"issue":"9","key":"1065_CR89","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"JP Huggins","year":"2012","unstructured":"Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153(9):1837\u201346.","journal-title":"Pain"},{"issue":"1","key":"1065_CR90","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/CORR.0000000000000339","volume":"477","author":"JM Jennings","year":"2019","unstructured":"Jennings JM, Williams MA, Levy DL, Johnson RM, Eschen CL, Dennis DA. Has self-reported marijuana use changed in patients undergoing total joint arthroplasty after the legalization of marijuana? Clin Orthop Relat Res. 2019;477(1):95\u2013100.","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"1065_CR91","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/08897077.2018.1449054","volume":"40","author":"AS Moon","year":"2019","unstructured":"Moon AS, Smith W, Mullen S, Ponce BA, McGwin G, Shah A, et al. Marijuana use and mortality following orthopedic surgical procedures. Substance Abuse. 2019;40(3):378\u201382.","journal-title":"Substance Abuse"},{"issue":"8","key":"1065_CR92","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.arth.2019.04.015","volume":"34","author":"JM Jennings","year":"2019","unstructured":"Jennings JM, Angerame MR, Eschen CL, Phocas AJ, Dennis DA. Cannabis use does not affect outcomes after total knee arthroplasty. J Arthroplasty. 2019;34(8):1667\u20139.","journal-title":"J Arthroplasty"},{"issue":"3","key":"1065_CR93","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bpa.2020.08.010","volume":"34","author":"AA Berger","year":"2020","unstructured":"Berger AA, Keefe J, Winnick A, Gilbert E, Eskander JP, Yazdi C, et al. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. Best Pract Res Clin Anaesthesiol. 2020;34(3):617\u201331.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"10","key":"1065_CR94","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1055\/s-0038-1669915","volume":"31","author":"M Roche","year":"2018","unstructured":"Roche M, Law TY, Sodhi N, Rosas S, Kurowicki J, Disla S, et al. Incidence of drug abuse in revision total knee arthroplasty population. J Knee Surg. 2018;31(10):928\u201333.","journal-title":"J Knee Surg"},{"issue":"4","key":"1065_CR95","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.arth.2019.11.035","volume":"35","author":"RM Vakharia","year":"2020","unstructured":"Vakharia RM, Sodhi N, Anis HK, Ehiorobo JO, Mont MA, Roche MW. Patients who have cannabis use disorder have higher rates of venous thromboemboli, readmission rates, and costs following primary total knee arthroplasty. J Arthroplasty. 2020;35(4):997\u20131002.","journal-title":"J Arthroplasty"},{"issue":"2","key":"1065_CR96","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","volume":"110","author":"MA Ware","year":"2010","unstructured":"Ware MA, Fitzcharles M-A, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604\u201310.","journal-title":"Anesth Analg"},{"issue":"2","key":"1065_CR97","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","volume":"9","author":"RQ Skrabek","year":"2008","unstructured":"Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164\u201373.","journal-title":"J Pain"},{"issue":"4","key":"1065_CR98","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860\u20139.","journal-title":"Pain"},{"issue":"4","key":"1065_CR99","doi-asserted-by":"publisher","first-page":"e18440","DOI":"10.1371\/journal.pone.0018440","volume":"6","author":"J Fiz","year":"2011","unstructured":"Fiz J, Dur\u00e1n M, Capell\u00e0 D, Carbonell J, Farr\u00e9 M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One. 2011;6(4):e18440.","journal-title":"PLoS One"},{"key":"1065_CR100","unstructured":"Gerardi MC, Batticciotto A, Talotta R, Chiara Ditto M, Atzeni F, Sarzi-Puttini P. Efficacy of cannabis flos in patients with fibromyalgia: a monocentric observational study.\u00a0[abstract]. Arthritis Rheumatol. 2016;68(10). https:\/\/acrabstracts.org\/abstract\/efficacy-of-cannabis-flos-in-patients-with-fibromyalgia-a-monocentric-observational-study\/. Accessed 29\u00a0March\u00a02022.\u00a0"},{"issue":"1","key":"1065_CR101","first-page":"53","volume":"38 Suppl 123","author":"V Giorgi","year":"2020","unstructured":"Giorgi V, Bongiovanni S, Atzeni F, Marotto D, Salaffi F, Sarzi-Puttini P. Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. Clin Exp Rheumatol. 2020;38 Suppl 123(1):53\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1065_CR102","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2217\/pmt-2016-0006","volume":"6","author":"A Okifuji","year":"2016","unstructured":"Okifuji A, Gao J, Bokat C, Hare BD. Management of fibromyalgia syndrome in 2016. Pain Manag. 2016;6(4):383\u2013400.","journal-title":"Pain Manag"},{"key":"1065_CR103","doi-asserted-by":"crossref","unstructured":"Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6):807.","DOI":"10.3390\/jcm8060807"},{"issue":"7","key":"1065_CR104","first-page":"Cd011694","volume":"7","author":"B Walitt","year":"2016","unstructured":"Walitt B, Klose P, Fitzcharles MA, Phillips T, H\u00e4user W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7(7):Cd011694.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"1065_CR105","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/annrheumdis-2016-eular.6288","volume":"75","author":"M Maccarrone","year":"2016","unstructured":"Maccarrone M. SP0105 biochemistry and pharmacology of the endocannabinoid system. Ann Rheum Dis. 2016;75(Suppl 2):26.","journal-title":"Ann Rheum Dis"},{"key":"1065_CR106","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.biocel.2018.04.010","volume":"99","author":"L Navarini","year":"2018","unstructured":"Navarini L, Bisogno T, Mozetic P, Piscitelli F, Margiotta DPE, Basta F, et al. Endocannabinoid system in systemic lupus erythematosus: first evidence for a deranged 2-arachidonoylglycerol metabolism. Int J Biochem Cell Biol. 2018;99:161\u20138.","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"1065_CR107","doi-asserted-by":"publisher","first-page":"e00394","DOI":"10.1002\/prp2.394","volume":"6","author":"SH Burstein","year":"2018","unstructured":"Burstein SH. Ajulemic acid: potential treatment for chronic inflammation. Pharmacol Res Perspect. 2018;6(2):e00394.","journal-title":"Pharmacol Res Perspect."},{"key":"1065_CR108","unstructured":"Katz-Talmor D, Kivity S, Blank M, Katz I, Perry O, Volkov A, et al. Cannabidiol treatment in a murine model of systemic lupus erythematosus accelerates proteinuria development.\u00a0Isr Med Assoc J. 2018;20(12):741\u2013745."},{"key":"1065_CR109","unstructured":"Warner L, Beg S. Utilization of complementary and integrative medicine among lupus patients: a patient centered analysis of perceived effectiveness and preference.[abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Accessed March 29, 2022. https:\/\/acrabstracts.org\/abstract\/utilization-of-complementary-and-integrative-medicine-among-lupus-patientsa-patient-centered-analysis-of-perceived-effectiveness-and-preference\/."},{"key":"1065_CR110","unstructured":"Karkache W, Ivory C. Survey of medical cannabis use in lupus and scleroderma.\u00a0\u00a0[abstract]. Arthritis Rheumatol. 2020;72(10). https:\/\/acrabstracts.org\/abstract\/survey-of-medical-cannabis-use-in-lupus-and-scleroderma\/. Accessed 29 March  2022.\u00a0"},{"key":"1065_CR111","doi-asserted-by":"crossref","unstructured":"Williams AR, Hill KP. Care of the patient using cannabis. Ann Intern Med. 2020;173(9):Itc65-itc80.","DOI":"10.7326\/AITC202011030"},{"key":"1065_CR112","doi-asserted-by":"crossref","unstructured":"Gunn JK, Rosales CB, Center KE, Nu\u00f1ez A, Gibson SJ, Christ C, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986.","DOI":"10.1136\/bmjopen-2015-009986"},{"issue":"42","key":"1065_CR113","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.2174\/1381612822666160805155922","volume":"22","author":"V Lorenzetti","year":"2016","unstructured":"Lorenzetti V, Alonso-Lana S, Youssef GJ, Verdejo-Garcia A, Suo C, Cousijn J, et al. Adolescent cannabis use: what is the evidence for functional brain alteration? Curr Pharm Des. 2016;22(42):6353\u201365.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"1065_CR114","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S2215-0366(14)70307-4","volume":"1","author":"E Silins","year":"2014","unstructured":"Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry. 2014;1(4):286\u201393.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"1065_CR115","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrn.2016.28","volume":"17","author":"HV Curran","year":"2016","unstructured":"Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293\u2013306.","journal-title":"Nat Rev Neurosci"},{"key":"1065_CR116","doi-asserted-by":"publisher","unstructured":"Fitzcharles M-A, Niaki OZ, Hauser W, Hazlewood G. Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases. J Rheumatol. 2019;46(5):532\u2013538. https:\/\/doi.org\/10.3899\/jrheum.181120.","DOI":"10.3899\/jrheum.181120"},{"issue":"11","key":"1065_CR117","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.amjmed.2019.05.017","volume":"132","author":"BC Foster","year":"2019","unstructured":"Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids: kinetics and interactions. Am J Med. 2019;132(11):1266\u201370.","journal-title":"Am J Med"},{"issue":"10","key":"1065_CR118","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1038\/s41386-018-0011-2","volume":"43","author":"ZD Cooper","year":"2018","unstructured":"Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046\u201355.","journal-title":"Neuropsychopharmacology"},{"key":"1065_CR119","first-page":"167","volume":"126","author":"LJ Crofford","year":"2015","unstructured":"Crofford LJ. Chronic pain: where the body meets the brain. Trans Am Clin Climatol Assoc. 2015;126:167\u201383.","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"2","key":"1065_CR120","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/acr.20362","volume":"63","author":"GH Louie","year":"2011","unstructured":"Louie GH, Tektonidou MG, Caban-Martinez AJ, Ward MM. Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey. Arthritis Care Res (Hoboken). 2011;63(2):247\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"1065_CR121","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/1759720X11408999","volume":"3","author":"MA Fitzcharles","year":"2011","unstructured":"Fitzcharles MA, Shir Y. Management of chronic pain in the rheumatic diseases with insights for the clinician. Ther Adv Musculoskelet Dis. 2011;3(4):179\u201390.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"1065_CR122","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1037\/a0035747","volume":"69","author":"DM Ehde","year":"2014","unstructured":"Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol. 2014;69(2):153\u201366.","journal-title":"Am Psychol"},{"issue":"2","key":"1065_CR123","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1515\/sjpain-2018-0023","volume":"18","author":"MM Mittinty","year":"2018","unstructured":"Mittinty MM, Vanlint S, Stocks N, Mittinty MN, Moseley GL. Exploring effect of pain education on chronic pain patients\u2019 expectation of recovery and pain intensity. Scand J Pain. 2018;18(2):211\u20139.","journal-title":"Scand J Pain"},{"issue":"1","key":"1065_CR124","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42238-021-00058-0","volume":"3","author":"KF Boehnke","year":"2021","unstructured":"Boehnke KF, Litinas E, Worthing B, Conine L, Kruger DJ. Communication between healthcare providers and medical cannabis patients regarding referral and medication substitution. J Cannabis Res. 2021;3(1):2.","journal-title":"J Cannabis Res"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-022-01065-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T06:41:29Z","timestamp":1651732889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-022-01065-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s11926-022-01065-7","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"16 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no relevant financial interests. Author Silverman is a member of the UCLA Cannabis Research Initiative.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}